Publications
Where expertise meets impact
Berry doesn’t just follow industry standards — we set them. Our team of award-winning statisticians, journal editors, and regulatory advisors leads the field in Bayesian and adaptive trial design. With research published in The New England Journal of Medicine, JAMA, and The Lancet, we’re driving innovation where it matters most.
Over 90% of our scientists published influential work this past year, advancing adaptive, Bayesian, and platform trial methodology. Our blend of academic rigor, regulatory insight, and real-world experience makes Berry a true authority in modern clinical trials.
Explore our most impactful peer-reviewed publications below.

JAMA Neurology
Neuroscience
Platform
Verdiperstat in Amyotrophic Lateral Sclerosis Results From the Randomized HEALEY ALS Platform Trial
February 17, 2025
2025
doi:10.1001/jamaneurol.2024.5249
JAMA
Neuroscience
Platform
CNM-Au8 in Amyotrophic Lateral Sclerosis The HEALEY ALS Platform Trial
February 17, 2025
2025
doi:10.1001/jama.2024.27643
JAMA Network Open
Neuroscience
Platform
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis A Randomized Clinical Trial
February 17, 2025
2025
doi:10.1001/jamanetworkopen.2024.59058
JAMA
Neuroscience
Platform
Pridopidine in Amyotrophic Lateral Sclerosis The HEALEY ALS Platform Trial
February 17, 2025
2025
doi:10.1001/jama.2024.26429
Stroke
Neuroscience
Stroke
Platform
Adaptive Platform Trials in Stroke
December 20, 2024
2024
doi.org/10.1161/STROKEAHA.124.045754
JAMA Network Open
Platform
The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design
December 11, 2024
2024
doi:10.1001/jamanetworkopen.2024.49998
Trials Journal
Infectious Disease
Platform
A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial
December 6, 2024
2024
doi: 10.1186/s13063-023-07718-x.
JCO Oncology Advances
Oncology
Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial
November 27, 2024
2024
doi.org/10.1200/OA-24-00044
No results found.
There are no results with this criteria. Try changing your search.